Insulet: 'We are well on our way'
By HME News Staff
Updated Thu February 22, 2018
BILLERICA, Mass. - Insulet Corp. reported revenue of $130.5 million for the fourth quarter of 2017, an increase of 26% compared to the same period in 2016. U.S. revenue from the Omnipod was $76.5 million, an increase of 21%. Full-year revenue was $463.8 million and U.S. revenue from the Omnipod was $271.6 million. Among Insulet's highlights for 2017: It received Medicare coverage under the prescription drug benefit for the Omnipod, paving the way to capturing an additional one-third of the U.S. market; it submitted Omnipod DASH, a mobile platform, for clearance by the U.S. Food and Drug Administration; and it broke ground on a new U.S. manufacturing facility. "Insulet had a very successful 2017 and our strong momentum this year gives us confidence for further improved performance in 2018," said Patrick Sullivan, chairman and CEO, in a release. “We are on a strong, sustainable growth trajectory and are well on our way to achieving our 2021 target of $1 billion in revenue.”
Comments